10Sep 2017

PHARMACOVIGILANCE: WHERE DO WE STAND?

  • Global Vigilance, Fresenius-Kabi Oncology Limited, Echelon Institutional Area, Plot No-11, Sector-32, Gurgaon-122001, Haryana, India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Pharmacovigilance is a system, not only significant to the early detection of adverse drug reactions; but also facilitates identification of risk in post marketing period. Contribution to Uppsala monitoring database from developing countries including India is still negligible due to the poor reporting culture, lack of knowledge in healthcare professionals regarding pharmacovigilance etc. are so many reason which are barrier for emerging this essential department in pharmaceutical industry. This article aims at bringing such issues into notice with respect to pharmacovigilance systems and look upon some measures that may be taken to safeguard the patients who take the drug for their better health, not for suffering the toxic effects, also some suggestion to improvising the health standards.


  1. Shuka SS, GidwaniBina, Pandey R, Rao SP, Singh V, Vyas Amber. Importance of Pharmacovigilance in Indian Pharmaceutical Industry. Asian J. Res. Pharm. Sci. 2012; Vol. 2: Issue 1, 04-08.
  2. A Kumar. Past, present and future of pharmacovigilance in India. 2011, Volume : 2, Issue : 1, 55--58
  3. BrahmachariBallari, Fernandes Melanie, and Bhatt Arun. Pharmacovigilance for clinical trials in India. Current practice and areas for reform PerspectClin Res. 2011 Apr-Jun; 2(2): 49?53.
  4. Murphy BM, Frigo LC. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital.?Hosp Pharm.?1993;28:1199?204.?240.
  5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients-a meta-analysis of prospective studies.?JAMA.?1998;279:1200?5.
  6. Woodward KN. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union. Journal of Veterinary Pharmacology and Therapeutics. Issue Volume 28, Issue 2, pages 131?147, April 2005
  7. Rehan HS, Sah RK, Chopra D. Comparison of knowledge, attitude and practices of resident doctors and nurses on adverse drug reaction monitoring and reporting in a tertiary care hospital. Indian J Pharmacol. 2012 Nov-Dec; 44(6): 699?703.
  8. Lisha Jenny John,MohamedArifulla, ?Jenny John Cheriathu, JayadevanSreedharan. Reporting of adverse drug reactions: an exploratory study among nurses in a teaching hospital, Ajman, United Arab Emirates. Daru.?2012;?20(1): 44.
  9. BavdekarSandeep and Karande Sunil. National pharmacovigilance program. January 17, 2006, Volume 43.
  10. Budhiraja, S., Akinapel, R. Biogenerics: Are we ready to take safety challenges in India. Indian Journal of Pharmacology. 2011; 43(3): 362-363
  11. Schedule Y. CDSCO, Ministry of Health and Family Welfare, Government of India, http://cdsco.nic.in/html/schedule-y%20(amended%20version-2005)%20original.htm.
  12. Prakash S. Pharmacovigilance in India.; Indian J Pharmacol. 200739:123.
  13. Lisha Jenny John,MohamedArifulla, ?Jenny John Cheriathu, JayadevanSreedharan. Reporting of adverse drug reactions: an exploratory study among nurses in a teaching hospital, Ajman, United Arab Emirates. Daru.?2012;?20(1): 44.
  14. Strandell J,?Noren GN,?Hagg S. Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports. Drug Saf.2013 Jan;36(1):63-70.

[Jitender Joshi, Rajul Rastogi, Rishi Kant Pandey and Amit Bihan. (2017); PHARMACOVIGILANCE: WHERE DO WE STAND? Int. J. of Adv. Res. 5 (9). 11-15] (ISSN 2320-5407). www.journalijar.com


Jitender Joshi


DOI:


Article DOI: 10.21474/IJAR01/5294       DOI URL: http://dx.doi.org/10.21474/IJAR01/5294


Share this article